Compare Globus Medical Inc. Class A Common Stock (GMED) vs Rivian Automotive, Inc. (RIVN) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

Rivian Automotive (RIVN) trades at $12.95, down 4.36% amid a bearish technical signal despite beating Q3 2026 delivery estimates with 19,248 vehicles. The company maintains negative profitability with a net income margin of -54.95% but shows improving revenue trends, reaching $5.39 billion in 2025. Cash flow remains negative, though operational losses have narrowed significantly from previous years.

The stock presents a high-risk opportunity with Wall Street consensus leaning bullish (48% buy ratings) and a $16.89 price target, implying potential upside. Key risks include persistent cash burn, intense EV competition, and execution challenges in scaling R2 production and autonomy technology, which are critical for achieving profitability.